Analyst Ratings For Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
Today, Goldman Sachs Group initiated coverage on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) with a Neutral.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) is Buy with a consensus target price of $37.50 per share, a potential 53.12% upside.
Some recent analyst ratings include
- 7/26/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- 7/17/2018-Wells Fargo & Co initiated coverage with a Outperform rating.
- 7/17/2018-William Blair initiated coverage with a Outperform rating.
- 7/17/2018-Jefferies Financial Group initiated coverage with a Buy rating.
Recent Trading Activity for Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL)
Shares of Autolus Therapeutics Ltd – ADR closed the previous trading session at 24,49 +0,14 0,57 % with 25.56 shares trading hands.